Cellular and molecular mechanisms in chronic obstructive pulmonary disease: An overview

Clinical and Experimental Allergy

Volumn 34, Issue 8, 2004, Pages 1156-1167

  Di Stefano, A ^a   Caramori, G ^b   Ricciardolo, F L M ^c   Capelli, A ^a   Adcock, I M ^d   Donner, C F ^a  

^a IRCCS   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STAT4 PROTEIN;

BRONCHUS BIOPSY; CELL INFILTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; GRANULOCYTE; HUMAN; IMMUNOREACTIVITY; INFLAMMATORY CELL; LUNG ALVEOLUS CELL; LUNG EMPHYSEMA; LUNG PARENCHYMA; MACROPHAGE; NEUTROPHIL; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SMOKING; T LYMPHOCYTE; UPREGULATION;

BRONCHI; CD8-POSITIVE T-LYMPHOCYTES; DNA-BINDING PROTEINS; HUMANS; LUNG; LYMPHOCYTE ACTIVATION; MACROPHAGES; NEUTROPHIL INFILTRATION; NF-KAPPA B; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; STAT4 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 4143086984     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2004.02030.x     Document Type: Review

References (81)

1. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS on behalf of the GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Global initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163:1256-76.
2. Siafakas NM, Vermeire P on behalf of the Task Force et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8:1398-420.
3. The COPD guidelines group of the standards of care committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 (Suppl. 5):S1-28.
4. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136:225-44.,
5. Ollerenshaw SL, Woolcock AJ. Characteristics of the inflammation in biopsies from large airways of subjects with asthma and subjects with chronic airflow limitation. Am Rev Respir Dis 1992; 145:922-7.
6. Saetta M, Di Stefano A, Maestrelli P et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993; 147:301-6.
7. Lacoste JY, Bousquet J, Chanez P et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993; 92:537-48.
8. Di Stefano A, Turato G, Maestrelli P et al. Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa. Am J Respir Crit Care Med 1996; 153:629-32.
9. Di Stefano A, Maestrelli P, Roggeri A et al. Upregulation of adhesion molecules in the bronchial mucosa of subjects with obstructive chronic bronchitics. Am J Respir Crit Care Med 1994; 149:803-10.
10. Di Stefano A, Capelli A, Lusuardi M et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998; 158:1277-85.
11. Di Stefano A, Capelli A, Lusuardi M et al. Decreased T-lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease. Clin Exp Allergy 2001; 31:893-902.
12. Vignola AM, Chanez P, Chiappara G et al. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 591-9.
13. Saetta M, Di Stefano A, Maestrelli P et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150:1646-52.
14. Zhu J, Qiu YS, Majumdar S et al. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 2001; 164:109-16.
15. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165:1592-6.
16. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:1304-9.
17. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998; 53:129-36.
18. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343:269-80.
19. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22:672-88.
20. Sutherland ER, Martin RJ. Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. J Allergy Clin Immunol 2003; 112:819-27.
21. Di Stefano A, Caramori G, Oates T et al. Increased expression of nuclear factor-kB in bronchial biopsies from smokers and patients with COPD. Eur Respir J 2002; 20:556-63.
22. O'Shaughmessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155:852-7.
23. Amadori A, Zamarchi R, De Silvestro G et al. Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med 1995; 1:1279-83.
24. Costabel U, Maier K, Teschler H, Wang YM. Local immune components in chronic obstructive pulmonary disease. Respiration 1992; 59 (Suppl. 1)17-9.
25. Hughes DA, Haslam PL, Townsend PJ, Turner-Warwick M. Numerical and functional alterations in circulatory lymphocytes in cigarette smokers. Clin Exp Immunol 1985; 61:459-66.
26. Zhu J, Majumdar S, Qiu Y et al. Interleukin-4 and interleukin-5 gene expression and inflammation in the mucus-secreting glands and subepithelial tissue of smokers with chronic bronchitis. Lack of relationship with CD8+ cells. Am J Respir Crit Care Med 2001; 164:2220-8.
27. Liu AN, Mohammed AZ, Rice WR et al. Perforin-independent CD8+ T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-α. Relative insensitivity to Fas Ligand. Am J Respir Cell Mol Biol 1999; 20:849-58.
28. Thierfelder WE, van Deursen JM, Yamamoto K et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 1996; 382:171-4.
29. Bacon CM, Petricoin III EF, Ortaldo JR et al. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc Natl Acad Sci USA 1995; 92:7307-11.
30. Di Stefano A, Caramori G, Capelli A et al. STAT-4 activation in smokers and patients with COPD. Eur Respir J 2004; 24:78-85.
31. Schulz C, Wolf K, Harth M, Kratzel K, Kunz-Schughart L, Pfeifer M. Expression and release of interleukin-8 by human bronchial epithelial cells from patients with chronic obstructive pulmonary disease, smokers, and never-smokers. Respiration 2003; 70:254-61.
32. Stanescu D, Sanna A, Veriter C et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996; 51:267-71.
33. Balzano G, Stefanelle F, Iorio C et al. Eosinophilic inflammation in stable chronic obstructive pulmonary disease. Relationship with neutrophils and airway function. Am J Respir Crit Care Med 1999; 160:1486-92.
34. Capelli A, Di Stefano A, Gnemmi I et al. Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics. Eur Respir J 1999; 14:160-5.
35. Thompson AB, Daughton D, Robbins RA, Ghafouri MA, Oehlerkin M, Rennard SI. Intraluminal airway inflammation in chronic bronchitis: characterization and correlation with clinical parameters. Am Rev Respir Dis 1989; 140:1527-37.
36. Suzuki T, Yamaya M, Sekizawa K et al. Bafilomycin A1 inhibits rhinovirus infection in human airway epithelium: effects on endosome and ICAM-1. Am J Physiol Lung Cell Mol Physiol 2001; 280:L1115-27.
37. Ricciardolo FLM, Di Stefano A. Smoking-induced corticosteroid resistance in asthma: 'the nitrosative stress hypothesis'. Am J Respir Crit Care Med 2004; 169:1252 [author reply: 1252-3].
38. Doring G, Frank F, Boudier C, Herbert S, Fleischer B, Bellon G. Cleavage of lymphocyte surface antigens CD2, CD4, CD8 by polymorphonuclear leukocyte elastase and cathepsin G in patients with cystic fibrosis. J Immunol 1995; 154:4842-50.
39. Capelli A, Di Stefano A, Lusuardi M, Gnemmi I, Donner CF. Increased macrophage inflammatory protein-1α levels in bronchoalveolar lavage fluid of patients affected by different stages of pulmonary sarcoidosis. Am J Respir Crit Care Med 2002; 165:236-41.
40. Van der Vliet A, Eiserich JP, Shigenaga MK, Cross CE. Reactive nitrogen species and tyrosine nitration in the respiratory tract. Epiphenomena or a pathobiologic mechanism of disease? Am J Respir Crit Care Med 1999; 160:1-9.
41. Schroder JM, Mrowietz U, Morita E, Christophers E. Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that locks interleukin-1 activity. J Immunol 1987; 139:3474-83.
42. de Boer WI, Sont JK, van Schadewijk A, Stolk J, van Krieken JH, Hiemstra PS. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol 2000; 190:619-26.
43. Cantor JO, Cerreta JM, Armand G, Osman M, Turino GM. The pulmonary matrix, glycosaminoglycans and pulmonary emphysema. Connect Tissue Res 1999; 40:97-104.
44. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and BPCO. Am J Respir Crit Care Med 1997; 155:542-8.
45. Confalonieri M, Mainardi E, Della Porta R et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998; 53:583-5.
46. Thompson AB, Mueller MB, Heires AJ et al. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. Am Rev Respir Dis 1992; 146:389-95.
47. Balbi B, Majori M, Bertacco S et al. Inhaled corticosteroids in stable BPCO patients: do they have effects on cells and molecular mediators of airway inflammation? Chest 2000; 117:1633-7.
48. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001; 15:1110-2.
49. Bocchino V, Bertorelli G, Bertrand LP et al. Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis. Allergy 2002; 57:17-22.
50. Qiu Y, Zhu J, Bandi V et al. Biopsy neutrophilia, chemokine and receptor gene expression in severe exacerbations of COPD. Am J Respir Crit Care Med 2003; 168:968-75.
51. Arias-Diaz J, Vara E, Torres-Melero J et al. Nitrite/nitrate and cytokine levels in bronchoalveolar lavage fluid of lung cancer patients. Cancer 1994; 74:1546-51.
52. Staal-van den Brekel AJ, Dentener MA, Drent M, Ten Velde GPM, Buurman WA, Wouters EFM. The enhanced inflammatory response in non-small cell lung carcinoma is not reflected in the alveolar compartment. Respir Med 1998; 92:76-83.
53. Weissler JC, Nicod LP, Toews GB. Pulmonary natural killer cell activity is reduced in patients with bronchogenic carcinoma. Am Rev Respir Dis 1987; 135:1353-7.
54. Pitchenik AE, Guffee J, Stein-Streilein J. Lung natural killer and interleukin-2 activity in lung cancer. A pulmonary compartment of augmented natural killer activity occurs in patients with bronchogenic carcinoma. Am Rev Respir Dis 1987; 136:1327-32.
55. Mullen JBM, Wright JL, Wiggs BR, Pare PD, Hogg JC. Reassessment of inflammation of airways in chronic bronchitis. Br Med J 1985; 291:1235-9.
56. Saetta M, Turato G, Facchini FM et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997; 156:1633-9.
57. Mullen JBM, Wright JL, Wiggs BR, Pare PD, Hogg JC. Structure of central airways in current smokers and ex-smokers with and without mucus hypersecretion: relationship to lung function. Thorax 1987; 42:843-8.
58. Neiwoehner DE, Kleinerman J, Rice DB. Pathologic changes in the airways of young cigarette smokers, N Engl J Med 1974; 291:755-8.
59. Bosken CH, Wiggs BR, Parè PD, Hogg JC. Small airway dimensions in smokers with obstruction to airflow. Am Rev Respir Dis 1990; 142:563-70.
60. Saetta M, Di Stefano A, Turato G et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:822-6.
61. Bosken CH, Hards J, Gatter K, Hogg J. Characterization of the inflammatory reaction in the peripheral airways of cigarette smokers using immunohistochemistry. Am Rev Respir Dis 1992; 145:911-7.
62. Lams BEA, Sousa AR, Rees PJ, Lee TH. Immunopathology of the small-airway submucosa in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158:1518-23.
63. De Boer WI, van Schadewijk A, Sont JK et al. Transforming growth factor β1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158:1951-7.
64. Aubert JD, Dalal BI, Bai TR, Roberts CR, Hayashi S, Hogg JC. Transforming growth factor beta 1 gene expression in human airways. Thorax 1994; 49:225-32.
65. Saetta M, Mariani M, Panina-Bordignon P et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165:1404-9.
66. Turato G, Zuin R, Miniati M et al. Airway inflammation in severe chronic obstructive pulmonary disease. Relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002; 166:105-10.
67. Grashoff WF, Sont JK, Sterk PJ et al. Chronic obstructive pulmonary disease: role of bronchial mast cells and macrophages. Am J Pathol 1997; 151:1785-90.
68. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 1995; 152:1666-72.
69. Retamales I, Elliott WM, Meshi B et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001; 164:469-73.
70. Saetta M, Baraldo S, Corbino L et al. CD8+ cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:711-7.
71. Majo J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J 2001; 17:946-53.
72. Rahman I, van Schadewijk AAM, Crowther AJL et al. 4-hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:490-5.
73. Harju T, Kaarteenaho-Wiik R, Soini Y, Sormunen R, Kinnula VL. Diminished immunoreactivity of γ-glutamylcysteine synthetase in the airways of smokers lung. Am J Respir Crit Care Med 2002; 166:754-9.
74. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 2001; 163:737-44.
75. Imai K, Dalal SS, Chen ES et al. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am J Respir Crit Care Med 2001; 163:786-91.
76. Churg A, Wang RD, Tai H et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-α release. Am J Respir Crit Care Med 2003; 167:1083-9.
77. van Straaten JFM, Coers W, Noordhoek JA et al. Proteoglycan changes in the extracellular matrix of lung tissue from patients with pulmonary emphysema. Mod Pathol 1999; 12:697-705.
78. van Straaten JFM, Postma DS, Coers W, Noordhoek JA, Kauffman HF, Timens W. Macrophages in lung tissue from patients with pulmonary emphysema express both inducible and endothelial nitric oxide synthase. Mod Pathol 1998; 11:648-55.
79. Lang MR, Fiaux GW, Gilloly M, Stewart JA, Hulmes DJS, Lamb D. Collagen content of alveolar wall tissue in emphysematous and nonemphysematous lungs. Thorax 1994; 49:319-26.
80. Cardoso WV, Sekhon HS, Hyde DM, Thurlbeck WM. Collagen and elastin in human pulmonary emphysema. Am Rev Respir Dis 1993; 147:975-81.
81. Vlahovic G, Russell ML, Mercer RR, Crapo JD. Cellular and connective tissue changes in alveolar septal walls in emphysema. Am J Respir Crit Care Med 1999; 160:2086-92.